Zilliant Unveils Next-Generation Price IQ ® : The Market’s Fastest and Most Transparent Price Optimization Application
Zilliant, the industry leader in intelligent end-to-end pricing solutions and sales guidance software, today announced Next-Generation Price IQ®, the next giant leap for its market-leading B2B price optimization solution.
Inflation has become the new business reality, exacerbated by supply chain turmoil, increased competition, and dramatic swings in both demand and inventory availability. As a result, B2B companies need a faster, more powerful approach to pricing that maintains market alignment while generating prices that are easily explainable and defensible.
Next-Generation Price IQ® delivers huge advances in performance, with a 10x improvement in AI-based optimization speeds. Now, businesses can quickly respond to rapidly changing business dynamics and market changes while providing unprecedented price transparency to sales teams.
“Leading the market in price optimization for two decades has revealed one critical truth: If sales reps don’t understand how a price is generated, they are unlikely to use it,” said Zilliant President and Chief Executive Officer Greg Peters. “That’s why I’m thrilled to announce today that Next-Generation Price IQ® provides a way to keep prices competitive amid near-constant change while also providing a pragmatic means to leverage AI with a crystal-clear view into how prices were derived.”
Other B2B pricing solutions make it impossible to understand how pricing was derived by tucking parameters, complex AI, and formulas out of sight and out of reach for users, or they generate pricing using strict rules that break as complexity increases. These methods fail to address volatile and competitive B2B markets.
In stark contrast, Next-Generation Price IQ® offers a transparent, proven and pragmatic pricing solution using data science and AI that’s both sophisticated and flexible. Most importantly, Zilliant is helping embroiled B2B companies navigate a supply-constrained, pandemic-disrupted, and inflationary time to meet and exceed their margin and revenue goals.
Zilliant’s next generation of price optimization empowers pricing teams to:
- Conduct goal-seeking, what-if scenarios to align business goals with pricing strategies
- Enforce rational price relationships such as minimum margin requirements and good-better-best product relationships
- Simultaneously visualize the predicted margin, revenue and volume impacts for various what-if scenarios before publishing optimized prices
- View precisely how the optimization engine produced each price, drill into each optimized price, view the associated transactions with inline analytics, make adjustments, and see how price changes will impact revenue and profit
- Immediately publish prices into CRM, CPQ, ERP, eCommerce or any other commercial system
No other price optimization solution in B2B can measure price elasticity, enforce rational price relationships, and conduct goal-seeking what-if scenarios in B2B. Where other applications use sequential rules or if-then statements, Next-Generation Price IQ® takes full advantage of constraint-based optimization to simultaneously account for business rules and price relationship requirements. Additionally, Zilliant is the only price optimization and management software company to offer a dedicated customer success team of industry, pricing, and data science experts to act as a strategic partner, delivering continuous value, change management guidance and precise measurement of adoption metrics, margin and revenue drivers, KPI trends, and pricing opportunity analyses.
Customers have reported a 10x ROI in less than a year with Zilliant’s price optimization solution; Next-Generation Price IQ® can be up and running in 90 days and lowers overall cost by supporting multiple pricing models and scenario templates, enabling simultaneous optimization of multiple lines of business within the same instance.
To learn more about Next-Generation Price IQ®, visit https://www.zilliant.com/products/priceiq.
About Zilliant
Zilliant powers intelligent commerce for B2B companies by connecting their commercial strategies with effective execution. Our industry-leading price optimization and management and sales guidance software enables profitable growth by transforming the way our customers use data to price and sell in traditional and digital channels. Zilliant’s data science, cloud-native software and passion for customer success delivers the highest ROI, fastest time to value and highest customer satisfaction. Learn more about how Zilliant helps power intelligence commerce at www.zilliant.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005036/en/
Contact information
Treble
Matt Grant
zilliant@treblepr.com
Danielle Schulz-Behrend
dschulzbehrend@zilliant.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press Release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
Safe Software Recognized as a Niche Player in 2025 Gartner® Magic Quadrant™ for Data Integration Tools15.12.2025 12:00:00 CET | Press Release
Safe Software, a global leader in data integration and transformation, has once again been recognized in the 2025 Gartner® Magic Quadrant™ for Data Integration Tools, marking the sixth consecutive year the company has been included in this prestigious report. Safe Software’s FME Platform has evolved well beyond its geospatial roots to become the only All-Data, Any-AI Integration Platform, empowering organizations worldwide to connect all data, applications, and AI technologies anywhere, at any scale, and with complete flexibility. With a community of more than 200,000 enthusiastic users and 25,000+ organizations in over 125 countries, FME continues to redefine data integration by delivering a no-code enterprise solution that unifies data movement, automation, and AI connectivity. “Our continued recognition reflects the trust of our customers and the innovation of our team,” said Don Murray, CEO and Co-Founder of Safe Software. “We’re proud to help organizations integrate data seamlessl
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 10:00:00 CET | Press Release
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c
BitGo yn Sicrhau Cymeradwyaeth OCC i Drosi i Fanc Ymddiriedolaeth Genedlaethol Siartredig Ffederal13.12.2025 02:13:00 CET | Pressmeddelande
Cyhoeddodd BitGo Holdings, Inc. (“BitGo”), y cwmni seilwaith asedau digidol, heddiw fod Swyddfa Rheolwr yr Arian Cyfred (“OCC”) wedi cymeradwyo ei gais i drosi BitGo Trust Company, Inc., cwmni ymddiriedolaeth siartredig De Dakota, i fanc cenedlaethol o'r enw BitGo Bank & Trust, National Association (N.A.). Gyda chymeradwyaeth OCC heddiw o'i drosi, mae is-gwmni Cwmni Ymddiriedolaeth BitGo bellach yn gweithredu fel BitGo Bank & Trust, National Association (N.A.). Bydd BitGo Bank & Trust, N.A. yn gweithredu o dan un gyfundrefn oruchwylio ffederal unffurf, gan ei alluogi i ddarparu'r eglurder, y llywodraethiant, a'r sicrwydd rheoleiddiol y mae sefydliadau'n eu disgwyl gan ymddiriedolwr a reoleiddir yn ffederal. Mae'r gymeradwyaeth hon yn atgyfnerthu safle BitGo fel sylfaen sefydliadol ar gyfer y system ariannol fodern, gan gyfuno goruchwyliaeth ar lefel banc â'r diogelwch, y cydymffurfiaeth, a'r graddadwyedd sy'n diffinio seilwaith BitGo. O dan siarter y banc cenedlaethol, ac yn amodol ar
FIA, Formula 1 Group and All 11 Race Teams Officially Sign the Ninth Concorde Agreement, Securing Strength and Stability for the Sport in Pivotal Five-Year Agreement12.12.2025 17:10:00 CET | Press Release
The Fédération Internationale de l'Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, and Formula 1 Group, the Commercial Rights Holder, have today announced the signing of the Concorde Governance Agreement, a crucial contract defining the regulatory framework and governance terms of the FIA Formula One World Championship until 2030. This follows the announcement in March that the 2026 Commercial Concorde Agreement had been signed by all the teams and Formula 1 Group. Together, these agreements constitute the ninth Concorde Agreement, representing a major step forward in the professionalisation and global development of the sport. First introduced in 1981, the Concorde Agreements are designed to promote sporting fairness, technological innovation and operational excellence, and align all key stakeholders around a shared vision for structured governance and continued growth of the sport. Each iteration of the Concorde Agr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
